RCMNY
ADVM

Rubric Capital Management (New York)’s Adverum Biotechnologies ADVM Stock Holding History

Rubric Capital Management (New York)’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-80,000
Closed -$2.8M – 56
2017
Q4 		$2.8M Buy
+80,000
New +$2.63M 0.35% 46

Other funds holding ADVM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Rubric Capital Management (New York)'s ADVM Position: Q1 2018 in Review

Rubric Capital Management (New York) sold out of Adverum Biotechnologies (ADVM) in Q1 2018, closing a stake of 80,000 shares — an estimated $2.8M sold.

Rubric Capital Management (New York) first reported a position in ADVM in Q4 2017 and held it in 1 quarter. The position peaked at $2.8M in Q4 2017. 96 funds tracked by Wall St. Rank hold ADVM as of Q1 2018.

  • Rubric Capital Management (New York) reported no remaining Adverum Biotechnologies position as of Q1 2018 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 80,000 Adverum Biotechnologies shares in Q1 2018, an estimated $2.8M.
  • Rubric Capital Management (New York) first reported a position in Adverum Biotechnologies in Q4 2017 and held it in 1 quarter.
  • Rubric Capital Management (New York)'s Adverum Biotechnologies position peaked at $2.8M in Q4 2017.
  • 96 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2018.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2018, filed 14 May 2018.